Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-daratumumab PET/CT in Multiple Myeloma
NCT04467281Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2020
- Primary completion
- Feb 2021
- Modality
- Antibody-Radionuclide Conjugates
01
Overview
A Phase 2 trial of zirconium Zr-89-DFO-daratumumab in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Planned start Jun 2020; status: withdrawn.
02
Drugs
zirconium Zr-89-DFO-daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04467281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04467281.